These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 10084642)

  • 1. Visual field "shimmering" associated with nefazodone.
    Greenberg WM
    J Clin Psychiatry; 1999 Feb; 60(2):124. PubMed ID: 10084642
    [No Abstract]   [Full Text] [Related]  

  • 2. Nefazodone and visual disturbances.
    Shuster J
    Nursing; 1999 Aug; 29(8):17. PubMed ID: 10504970
    [No Abstract]   [Full Text] [Related]  

  • 3. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M; Cubbidge RP; Hosking SL
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nefazodone-induced visual disturbances.
    Mosberian P; Leung M; Hollander Y; Remick RA
    Can J Psychiatry; 1999 Nov; 44(9):925-6. PubMed ID: 10584168
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug toxicity and visual fields.
    Applebaum M
    J Am Optom Assoc; 1980 Sep; 51(9):859-62. PubMed ID: 7451802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyskinetopsia during light adaptation associated with nefazodone treatment.
    Hundal KS; Chen S; Moore W; Tranos P; Joshi N
    Eye (Lond); 2003 Nov; 17(9):1040-2. PubMed ID: 14704758
    [No Abstract]   [Full Text] [Related]  

  • 9. Visual field defect and intracerebral hemorrhage associated with use of vardenafil (Levitra).
    Hellstrom WJ
    Neurology; 2006 Jan; 66(2):293-4; author reply 293-4. PubMed ID: 16434684
    [No Abstract]   [Full Text] [Related]  

  • 10. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
    Best JL; Acheson JF
    Eye (Lond); 2005 Jan; 19(1):41-4. PubMed ID: 15094729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vigabatrin and epilepsy: further lessons in early childhood.
    Parisi P; Bombardieri R; Curatolo P
    Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225
    [No Abstract]   [Full Text] [Related]  

  • 13. Vigabatrin and visual field disorders.
    Prescrire Int; 2002 Dec; 11(62):182. PubMed ID: 12472095
    [No Abstract]   [Full Text] [Related]  

  • 14. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Striking accumulation of vascular-induced homonymous defects of the visual field in young women].
    Eicholtz W
    MMW Munch Med Wochenschr; 1975 Apr; 117(14):571-4. PubMed ID: 806788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central and peripheral vision loss associated with nefazodone usage.
    Luu C; Kiely P; Crewther D; Kowal L; Crewther S
    Doc Ophthalmol; 2003 May; 106(3):319-25. PubMed ID: 12737510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Visual field defect in a patient given sodium valporate then carbamazepine: possible effect of aminotransferase inhibition].
    Jung P; Doussard-Lefaucheux S
    Rev Neurol (Paris); 2002 Apr; 158(4):477-9. PubMed ID: 11984493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Constriction of the visual field by vigabatrin].
    Asensio Sánchez VM
    An Med Interna; 2002 Dec; 19(12):655-6. PubMed ID: 12593042
    [No Abstract]   [Full Text] [Related]  

  • 19. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
    Manuchehri K
    BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
    [No Abstract]   [Full Text] [Related]  

  • 20. The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
    Kumar N; Jivan S
    Eye (Lond); 2006 Sep; 20(9):1082-3; author reply 1083-4. PubMed ID: 16244645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.